Exome sequencing of 22 Pheochomocytoma/Paraganglioma (PPGL) tumors
Exome sequencing of 22 Pheochomocytoma/Paraganglioma (PPGL) primary tumors, both malignant and non-malignant. Tumor material was from snap-frozen (SF) or formalin-fixed-paraffin-embedded (FFPE) .
- 22 samples
- DAC: EGAC00001000411
- Technologies: Illumina HiScanSQ, NextSeq 500
DATA ACCESS AGREEMENT CGNT- GROUP COMMITTEE This agreement governs the terms on which access will be granted to the Exome sequencing data generated by the Clinical Genetics Neural Tumor (CGNT)-group at University of Gothenburg.
This agreement governs the terms on which access will be granted to the Exome sequencing data generated by the Clinical Genetics Neural Tumor (CGNT)-group at University of Gothenburg. In signing this agreement, You are agreeing to be bound by the terms and conditions of access set out in this agreement. For the sake of clarity, the terms of access set out in this agreement apply both to the User and the User’s Institution (as defined below). User Institution and User are referred to within the agreement as “You” and “Your” shall be construed accordingly. Definitions: CGNT-group committee means senior investigators and medical doctors affiliated to the “neural tumor group” at Sahlgrenska University Hospital in Gothenburg granting data access: • MD, PhD Andreas Muth, Section for Endocrine Surgery and Abdominal Sarcoma, Department of Surgery, Sahlgrenska University Hospital and Institute of Clinical Sciences, Sahlgrenska Academy at the University of Gothenburg, Sweden. • MD Prof. Ola Nilsson Wassén, Sahlgrenska Cancer Center, Institute of Biomedicine, Sahlgrenska Academy at the University of Gothenburg, Sweden. • MD Prof. Bo Wängberg, Section for Endocrine Surgery and Abdominal Sarcoma, Department of Surgery, Sahlgrenska University Hospital and Institute of Clinical Sciences, Sahlgrenska Academy at the University of Gothenburg, Sweden. • PhD Frida Abel, Department of Clinical Genetics and Genomics, Sahlgrenska University Hospital and Institution of Biomedicine, Sahlgrenska Academy at the University of Gothenburg, Sweden. Data means all and any human genetic data obtained from the CGNT-group. Data Subject means a person, who has been informed of the purpose for which the Data is held and has given his/her informed consent thereto. User means a researcher who’s User Institution has previously completed this Data Access Agreement and has received acknowledgement of its acceptance. Publications means, without limitation, articles published in print journals, electronic journals, reviews, books, posters and other written and verbal presentations of research. User Institution means the organisation at which the User is employed, affiliated or enrolled. Terms and Conditions: In signing this Agreement: 1. You agree to use the Data only for the advancement of medical research, according to the consent obtained from sample donors. 2. You agree not to use the data for the creation of products for sale or for any commercial purpose. 3. You agree to preserve, at all times, the confidentiality of information and Data pertaining to Data Subjects. In particular, You undertake not to use, or attempt to use the Data to compromise or otherwise infringe the confidentiality of information on Data Subjects and their right to privacy. 4. You agree not to attempt to link the data provided under this agreement to other information or archive data available for the data sets provided, even if access to that data has been formally granted to you, or it is freely available without restriction, without specific permission being sought from the CGNT-group committee. 5. You agree not to transfer or disclose the Data, in whole or part, or any identifiable material derived from the Data, to others, except as necessary for data/safety monitoring or programme management. Should You wish to share the Data with a collaborator outwith the same Institution, the third party must make a separate application for access to the Data. 6. You agree to use the data for the approved purpose and project described in your application; use of the data for a new purpose or project will require a new application and approval. 7. You accept that Data will be reissued from time to time, with suitable versioning. If the reissue is at the request of sample donors and/or other ethical scrutiny, You will destroy earlier versions of the Data. 8. You agree to abide by the terms outlined in the Consortium 'Publications Policy' as set out in Schedule 1. 9. You agree to acknowledge in any work based in whole or part on the Data, the published paper from which the Data derives. Suitable wording is provided in the Publications Policy given in Schedule 1. 10. You accept that the CGNT-group, the original data creators, depositors or copyright holders, or the funders of the Data or any part of the Data supplied: a) bear no legal responsibility for the accuracy or comprehensiveness of the Data; and b) accept no liability for indirect, consequential, or incidental, damages or losses arising from use of the Data, or from the unavailability of, or break in access to, the Data for whatever reason. 11. You understand and acknowledge that the Data is protected by copyright and other intellectual property rights, and that duplication, except as reasonably required to carry out Your research with the Data, or sale of all or part of the Data on any media is not permitted. 12. You recognise that nothing in this agreement shall operate to transfer to the User Institution any intellectual property rights relating to the Data. The User Institution has the right to develop intellectual property based on comparisons with their own data. 13. You accept that this agreement will terminate immediately upon any breach of this agreement by You and You will be required to destroy any Data held. 14. You accept that it may be necessary for the CGNT-group committee or its appointed agent to alter the terms of this agreement from time to time in order to address new concerns. In this event, the Consortium or its appointed agent will contact You to inform You of any changes and You agree that Your continued use of the Data shall be dependent on the parties entering into a new version of the Agreement. 15. You agree that you will submit a report to the CGNT Data Access Committee, if requested, on completion of the agreed purpose. The CGNT Data Access Committee agrees to treat the report and all information, data, results, and conclusions contained within such report as confidential information belonging to the User Institution. 16. You accept that the Data is protected by and subject to international laws, and that You are responsible for ensuring compliance with any such applicable law. The CGNT Data Access Committee reserves the right to request and inspect data security and management documentation to ensure the adequacy of data protection measures in countries that have no national laws. 17. This agreement shall be construed, interpreted and governed by the laws of Sweden and shall be subject to the non-exclusive jurisdiction of the Swedish courts. SCHEDULE 1 Publications Policy The primary purpose of the CGNT-group at University of Gothenburg is to identify genome sequence variants influencing causes of morbidity and mortality in patients with solid neural tumors, through implementation and analysis of genomic studies. Additional objectives include the development and validation of bioinformatics tools and diagnostic solutions facilitating health care and personalized medicine. The CGNT-group anticipates that data generated from the study will be used by others, such as required for developing new methods, in understanding patterns of variants involved in neural tumor diseases. Authors who use data from the project must acknowledge the CGNT-group using the following wording "This study makes use of exome sequencing data generated by the Neural tumor group at Department of Clinical Genetics, University of Gothenburg (Wilzén et al., Int J Cancer. 2016 May 1;138(9):2201-11 and Tomic et al., PLoS Genet. 2020 Apr)”. Users should note that the CGNT-group bears no responsibility for the further analysis or interpretation of these data, over and above that published by the CGNT-group. For and on behalf of User: Name of Applicant: _____________________________________ _____________________________________ _____________________________________ _____________________________________ Signature of Applicant(s): _____________________________________ _____________________________________ _____________________________________ _____________________________________ Date: _____________________________________ For and on behalf of User Institution: Signature of Institutional or Administrative Authority: _____________________________________ Print name: _____________________________________ User Institution: _____________________________________ Date: _____________________________________ WHEN SUBMITTING THIS DOCUMENT, PLEASE INCLUDE ALL PAGES OF THE AGREEMENT WITH THIS SIGNATURE PAGE
Studies are experimental investigations of a particular phenomenon, e.g., case-control studies on a particular trait or cancer research projects reporting matching cancer normal genomes from patients.
Study ID | Study Title | Study Type |
---|---|---|
EGAS00001003991 | Other |
This table displays only public information pertaining to the files in the dataset. If you wish to access this dataset, please submit a request. If you already have access to these data files, please consult the download documentation.